DreaMed Gets Additional FDA Clearance for Diabetes Analyzer

October 12, 2021

DreaMed has received 510(k) clearance from the FDA for its Advisor Pro artificial intelligence-based clinical decision support software for diabetes patients.

Advisor Pro is designed to optimize insulin dosing for patients who use insulin pumps or injections and who monitor their glucose using a continuous glucose monitor or blood glucose meter.

The new clearance expands the platform's target population to include patients with type 2 diabetes. This is the fourth 510(k) clearance the Israel-based company has received for the system, which was originally cleared for use by type 1 diabetes patients.

View today's stories